The Hidden Mystery Behind Single-use Bioprocessing Market

Increasing Demand For Biopharmaceuticals 

Single-use bioprocessing reduces the initial investment and R&D cost. These technologies have a low cost of labor and material and are easily disposed of. In addition, these single-use bioprocessing plants have around 35% more favorable CO2 balance compared to stainless steel reactors which are used in conventional bioprocessing owing to which these are highly adopted by the manufacturer. In 2018, Merck invested EUR 40 million (~USD 48 million), to build a robust manufacturing and distribution platform in Asia, over two years. This investment followed Merck’s announcement of a EUR-80-million life science investment in China in the year 2016 will also accelerate Merck’s Mobius single-use manufacturing in China, for the development of biosimilars. With the outbreak of the COVID-19 pandemic, there is a high demand for vaccines. Several bioprocessing processes are being leveraged for the development of vaccines against coronaviruses. For instance, several COVID-19 vaccine efforts are harnessing platforms that are based on single-use technologies. These efforts involve the use of novel approaches, such as mRNA and DNA technologies. Also, the rising popularity, growing awareness, and high adoption rate by several manufacturers like CMOS, OEM, and in-house manufacturers have promoted the growth of the le-usee bioprocessing market.

Technological Advancement In Single-use Bioprocessing Systems

The market is witnessing technological advancement in the development of single-use bioprocessing systems. For instance, in February 2019, Applikon Biotechnology B.V. launched the single-use AppliFlex ST lab-scale bioreactor as a significant extension to its range of innovative bioreactor systems. AppliFlex ST is a fully customizable and scalable stirred-tank single-use bioreactor that uses 3D printing technology to provide a head plate that is uniquely configured to each process, including custom impeller design, and different sample port connections. The 3D printing production technology had allowed multiple options such as designing on-demand impellers in Helical, Hydrofoil, Marine, or Rushton formats. It provides complete reproducibility between the different customized bioreactors, providing identical conditions between runs. There is an increase in the launch of single-use bioprocessing systems. For instance, in September 2019, ABEC launched a single-use bioreactor system with a working volume of 6,000 L three times that of the industry’s standard upper limit. In January 2019, Sartorius Stedim Biotech launched the Biostat RM TX with Flexsafe RM TX for producing consistent quality cellular products. Biostat RM TX is a single-use bioreactor, a new wave-mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies. It combines single-use Flexsafe bag technology with the company’s expertise in biopharmaceutical automation. Biostat RM TX is designed for scale-out expansion of cells including patient-specific T cells and is a closed system, consisting of an automated control unit and up to two rocking platforms to gently agitate single-use Flexsafe RM TX bags.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com